CoChat

Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study

Open access
D’Erasmo, Laura, Steward, Kim, Cefalù, Angelo Baldassare, Di Costanzo, Alessia, Boersma, Eric, Bini, Simone, Arca, Marcello, van Lennep, Jeanine Roeters, the Italian and European Working Group on Lomitapide in HoFH, D’Erasmo, Laura, Cefalù, Angelo Baldassare, Di Costanzo, Alessia, Bini, Simone, Giammanco, Antonina, Averna, Maurizio, Iannuzzo, Gabriella, Fortunato, Giuliana, Gentile, Marco, Puja, Arturo, Montalcini, Tiziana, Pavanello, Chiara, Calabresi, Laura, Vigna, Giovanni Battista, Bucci, Marco, Bonomo, Katia, Nota, Fabio, Sampietro, Tiziana, Sbrana, Francesco, Suppressa, Patrizia, Sabbà, Carlo, Fimiani, Fabio, Cesaro, Arturo, Calabrò, Paolo, Ventura, Fulvio, D’Addato, Sergio, Pisciotta, Livia, Bertolini, Stefano, Arca, Marcello, Kolovou, Genovefa, Liberopoulos, Evangelos, Daphnis, Eugene, van Lennep, Jeanine Roeters, Rutten, Joost, Boersma, Eric, Steward, Kim, Vogt, Anja, Cegla, Jaimini, Walji, Shahenaz, Kayikcioglu, Meral, Real, José, Martínez-Hervás, Sergio, Ellis, Avishay, Littmann, Karin · 2022 · European Journal of Preventive Cardiology
Cited by 71

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Aims: Lomitapide is a lipid-lowering agent indicated as an adjunct therapy for adult homozygous familial hypercholesterolaemia (HoFH). This study evaluated the medium-term effectiveness and safety of lomitapide in a large cohort of HoFH patients in Europe. Methods and results: In a multicentre retrospective, observational study including 75 HoFH patients treated with lomitapide in a real-world clinical setting from 9 European countries, low-density lipoprotein cholesterol (LDL-C) changes, adverse events (AEs), and major adverse cardiovascular events (MACE) were assessed. After a median 19 months (interquartile range 11–41 months) of treatment with a mean dosage of 20 mg of lomitapide. Low-density lipoprotein cholesterol decreased by 60%, from baseline 280.5 mg/dL (191.8–405.0 mg/dL) to 121.6 mg/dL (61.0–190.5 mg/dL). At the last visit, 32.0% of patients achieved LDL-C <100 mg/dL and 18.7% <70 mg/dL. At baseline, 38 HoFH patients were receiving LDL apheresis (LA), but after initiation of lomitapide 36.8% of patients discontinued LA. During follow-up, lomitapide was permanently interrupted in 13% of patients. Gastrointestinal AEs occurred in 40% and liver transaminases increased (3–5 × upper limits of normal) in 13% of patients. Among patients with liver ultrasound evaluation (n = 45), a modest increase in hepatic steatosis was noted during treatment; however, liver stiffness measured by elastography in 30 of them remained within the normal range. Among HoFH patients exposed to lomitapide for at least 2 years, MACE incident rate was 7.4 per 1000 person-years in the 2 years after as compared to 21.2 per 1000 person-years before treatment with lomitapide. Conclusion: In this medium-term real-world experience, lomitapide proved to be very effective in reducing LDL-C in HoFH. Gastrointestinal AEs were common, but liver safety was reassuring with no sign of increased risk of liver fibrosis. A signal of cardiovascular protection was also observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjpc/zwab229

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 71

Metadata

Authors
D’Erasmo, L., Steward, K., Cefalù, A. B., Di Costanzo, A., Boersma, E., Bini, S., Arca, M., van Lennep, J. R., the Italian and European Working Group on Lomitapide in HoFH, D’Erasmo, L., Cefalù, A. B., Di Costanzo, A., Bini, S., Giammanco, A., Averna, M., Iannuzzo, G., Fortunato, G., Gentile, M., Puja, A., Montalcini, T., Pavanello, C., Calabresi, L., Vigna, G. B., Bucci, M., Bonomo, K., Nota, F., Sampietro, T., Sbrana, F., Suppressa, P., Sabbà, C., Fimiani, F., Cesaro, A., Calabrò, P., Ventura, F., D’Addato, S., Pisciotta, L., Bertolini, S., Arca, M., Kolovou, G., Liberopoulos, E., Daphnis, E., van Lennep, J. R., Rutten, J., Boersma, E., Steward, K., Vogt, A., Cegla, J., Walji, S., Kayikcioglu, M., Real, J., Martínez-Hervás, S., Ellis, A., & Littmann, K.
Venue
European Journal of Preventive Cardiology
Published
2021-12-31
Volume
29
Issue
5
Pages
832-841
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W4206437067
Cited by
71
References
2
FWCI
8.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. https://app.cochat.ai/papers/10.1093/eurjpc/zwab229
The paper
D’Erasmo, L., Steward, K., Cefalù, A. B., Di Costanzo, A., Boersma, E., Bini, S., Arca, M., van Lennep, J. R., the Italian and European Working Group on Lomitapide in HoFH, D’Erasmo, L., Cefalù, A. B., Di Costanzo, A., Bini, S., Giammanco, A., Averna, M., Iannuzzo, G., Fortunato, G., Gentile, M., Puja, A., . . . Littmann, K. (2022). Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwab229

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.